Product logins

Find logins to all Clarivate products below.


Alison Isherwood

Director, Epidemiology & Real-World Evidence

Dr. Alison Isherwood is a Director in Clarivate’s Commercial Strategy Consulting Epidemiology & Real-World Evidence team.

Alison has over 16 years of consultancy experience in healthcare and life sciences consultancy, specializing in epidemiological and RWE-based insights and solutions. Her role is to use secondary data and US and European real-world data (RWD) to provide strategic epidemiological insights for business stakeholders in commercial and HEOR roles.

Alison held the roles of Research Scientist at Evidera designing and executing RWE-based outcomes research studies. Prior to this, she the Director of Epidemiology for DRG’s Syndicated Epidemiology team where she gained considerable experience in patient population sizing with incidence and prevalence risk-based forecast modelling across a portfolio of 200 diseases in over 40 countries.

She holds a Doctoral degree from the University of Reading (UK), and an MSc in Epidemiology, an MRes in Life Sciences and a BSc in Medical Microbiology all from the University of Edinburgh.


arrow_forward
Get in touch with Alison

Latest news

News May 13, 2026
Clarivate Identifies Five Medtech Trends Set to Redefine Growth Opportunities in 2026

New Medtech Trends to Watch report highlights market shifts, care delivery changes and competitive dynamics poised to reshape medtech strategy London, U.K.  May 13, 2026. Clarivate Plc (NYSE:CLVT), a leading…

News May 6, 2026
Clarivate launches Web of Science Research Intelligence

AI-native research intelligence platform for research funding, strategy and impact now available globally to institutions LONDON, UK — May 6, 2026: Clarivate Plc (NYSE: CLVT), a leading global provider of…

News April 29, 2026
Clarivate Reports First Quarter 2026 Results

— Value Creation Plan delivering accelerated organic revenue growth — — Utilized solid free cash flow generation to deleverage — — Reaffirms 2026 financial outlook — London, UK — April…

Related resources

How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center